Article

Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit

Figure 5. Numbers of cardiovascular events are the differences between the MI rates (aspirin rate − aspirin rate × risk ratio) plus the difference in stroke rates (baseline rates not shown) multiplied by 1000 patient-years. The number of bleeding episodes represents the difference in bleeding rates (combination rate − combination rate/risk ratio for major bleeding episode) multiplied by 1000. Letters and corresponding dots represent actual combinations of bleeding and cardiovascular risk from . The shaded area in the parallelogram represents unfavorable risk or benefit. APRICOT-2 = Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2; ASPECT-2 = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2; ATACS = Antithrombotic Therapy in Acute Coronary Syndromes; OASIS = Organization to Assess Strategies for Ischemic Syndromes; WARIS II = Warfarin, Aspirin, Reinfarction Study. Predicted myocardial infarctions (MIs) and thrombotic strokes averted and excess bleeding episodes caused in 1000 patients as a result of adding warfarin to aspirin for 1 year, stratified by bleeding and MI risk.Table 2